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Abstract 
 
Objectives 
The objective of the authors was to provide an up-to-date review about the epidemiology, diagnosis 
and surgical management of the malignant primary sacral tumors. 
 
Methods 
A PubMed search was conducted using a combination of the following items: (("Spinal 
Neoplasms"[Mesh]) AND "Sacrum"[Mesh]) NOT ("Metastasis" OR "Metastases" OR "Benign"). The 
literature review and the author's own surgical experiences were used to assess the current 
treatment strategies of the malignant sacral tumors. 
 
Results 
Twenty case series were identified, which studies discuss in detail the surgical strategies, the 
postoperative complications, the functional and onclolgic outcome, the recurrence free and the 
disease specific survival of this rare patient category. 
 
Discussion 
Sacral tumors are rare pathologies. Their management generates a complex medical problem, as 
they usually are diagnosed in advanced stages with extended dimensions involving the sacral nerves 
and surrounding organs. The evaluation and complex treatment of these rare tumors require a 
multidisciplinary approach, optimally at institutions with comprehensive care and experience. 
Although conventional oncologic therapeutic methods should be used as neoadjuvant or adjuvant 
therapies in certain histological types, en bloc resection with wide surgical margins is essential for 
long-term local oncologic control. This is often technically difficult to achieve, as just a few centers in 
the world perform sacral tumor surgeries on a regular basis, and have enough wide experience. 
Therefore international cooperation and organization of multicenter tumor registries are essential to 
develop evidence based treatment protocols. 
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Introduction 
Primary malignant tumors of the sacrum are rare1. The majority of them are low-grade malignancies 
like chordoma and chondrosarcoma, characterized by slow growth and long standing nonspecific 
initial symptoms2. In contrast, Ewing sarcoma, osteosarcoma and other high-grade neoplasms may 
have more aggressive and dramatic presentation3.  
The effective treatment of these rare conditions requires a multidisciplinary team, including 
oncologists, radiologists, radiotherapists and spine surgeons4. The fundamental step of the diagnostic 
process (preceded by proper clinical, morphological and functional studies, including laboratory 
tests) is the biopsy5. After establishing the pathological diagnosis, the team should plan the proper 
structure of the multimodular-, histotype- and patient specific treatment4. Due to the permanent 
progress in oncology, the therapeutic strategies in some tumor types are changing dramatically. For 
example, a decade ago the treatment of choice in Ewing sarcoma was surgical intervention. Today, 
due to the effective drug development strategies, the surgical intervention has become a last step, 
used only in some cases after ineffective chemotherapy3. In chordomas, proton and carbon beam 
therapy are successfully used in the treatment of clival lesion. However surgery is still the first choice 
of treatment in the case of large sacrococcygeal chordoma2. Similarly, in case of a sacral 
chondrosarcoma there are no widely accepted and accessible chemo- or radiotherapeutic treatment 
protocols. Thus en bloc surgical resection is the eligible curative treatment method2. In most cases 
wide resection of these tumors is the only option to achieve local control and long term survival, 
however adjuvant radiotherapy can multiply the disease-free survival6. The local recurrence rate 
after surgery, due to the complex anatomy of the sacral region and the difficulty to achieve tumor 
free margins, is relatively high7. 
The different surgical treatment methods of sacral tumors have shown a similarly fast evolution. The 
spine tumor centers that treat a fair number of cases have contributed to build international 
databases and to develop the basic surgical principles48. The objective of the present paper is to give 
an updated literature overview about the surgical management of the primary malignant tumors of 
the sacrum. 
Epidemiology of primary malignant sacral tumors  
Spinal malignant primary bone tumors are rare, they are accounting for less than 5% of all osseous 
neoplasms, and less than 0.2% of all cancers9. According to the results of large scale population 
registries, the incidence of primary sacral tumors varies between 32% and 71% of all primary spinal 
tumors10, 11. The most common primary malignant tumors of the sacrum are chordoma and sacral 
sarcomas like chondrosarcoma, osteosarcoma and Ewing sarcoma12.  
Chordoma is the most common primary spinal tumor with an overall incidence of 0.08 per 100,000 
individuals accounting for 40% of all primary sacral tumors13. The male:female prevalence ratio is 2:1 
with an increasing incidence after the fourth decade14. These lesions arise from notochordal 
remnants within the vertebral bodies and sacrum and are considered slow growing, locally aggressive 
lesions. Median overall survival is estimated to 7.7 years in the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute (1973-2009)13. 
Chondrosarcoma has an overall incidence of 0.5 per 100,000 per year, although its sacral localization 
is below 5% of all cases15. It is more common in males aged between 30-70 years, with a peek in the 
fifth decade. Chondrosarcoma may arise as primary tumor or as secondary transformation of an 
osteochondroma or enchondroma16. 
Ewing's sarcoma and the PNET-group are the second most frequent primary malignant bone cancers 
in children and adolescents with an overall incidence is less than 0.2 per 100,000 per year17. They 
involve the spine primarily in 3 to 10% of cases 18, sacrum being the most involved spinal level19. The 
male female ratio for Ewing’s sarcoma is 3:1, it affects young people between 5 to 30 years. Seventy 
five percent of this tumor occurs in the first two decade18. 
Osteosarcoma is the most common primary bone tumor but rarely affects the spine20, accounting for 
only 4% of primary sacral tumors21. Many of the osteosarcomas that occur in the sacrum are 
secondary to degeneration of Paget disease18. 
Clinical appearance and diagnosis 
Each patient suspected of having a primary sacral tumor should undergo a thorough local and 
systemic work-up. Imaging studies give information about the extension of the tumor, but the 
fundamental component of the staging procedure is the histopathological examination. 
The clinical presentation of  sacral tumors depends mainly on the anatomical location of the lesion 
within the sacrum and it is influenced by the aggressiveness of the neoplasm22.  Majority of the 
patients initially report low back or buttock pain but a painless visible sacral mass can also be the first 
sign of the disease. The pain is secondary due to mass effect and to the erosion and impingement of 
the surrounding structures6. Pain may be present with or without neurologic symptoms. Numbness, 
loss of sensation, decreased reflexes, sphincter dysfunction or motor deficit can be also the first sign. 
A specific concordance of sensory, motor, and vegetative symptoms may suggest the development of 
cauda equina syndrome requiring urgent surgical intervention23. A large presacral mass may be 
palpable on digital rectal examination, and due to obstruction can cause constipation. Invasion of the 
sacroiliac joint can cause discomfort or even pain during sitting or walking. Weight loss, general 
weakness and other general neoplastic signs are the characteristic of metastatic lesions rather than 
primary sacral tumors1. 
Plain radiography is often the first imaging modality performed but it has limited sensitivity18. 
Amorosa et al. demonstrated in their study in patients with proven sacral pathological lesions that 
the accuracy of the initial radiologic evaluation can be as low as 17%24. More accurate visualization of 
the region can be obtained by using computerized tomography (CT) or magnetic resonance imaging 
(MRI).  In most cases, both should be performed, because of the different characteristics of the two 
methods6. CT scans show well the osseous relations, as well as intratumoral calcification. Rectal or 
venous contrast can be administered to visualize the involvement of pelvic structures6. The possibility 
of three-dimensional reconstruction is a great advantage of the CT scan.  However, MRI is the 
imaging modality of choice in the case of sacral neoplasms, because it allows a clearer definition of 
soft tissue involvement. The combination of T1- and T2-weighted imaging is suitable to define tumor 
size, location and other characteristic features and may yield enough information for presumptive 
diagnosis6. Bone scintigraphy is widely used to determine whether the lesion is monostotic or 
polyostotic, and to search for bone metastases 25. Most primary sacral tumors have an increased 
uptake on bone scan, but lacks specificity to identify the nature of an abnormality. A more advance 
form of scintigraphy is the SPECT, which has been shown to increase the diagnostic usefulness of 
bone scan by improving its specificity and sensitivity. It has a superior ability to detect lesions 
otherwise missed on CT or MRI examinations26.  Although, some sacral tumor types have specific CT 
or MRI signs (Table 1.) 14, 16, 18, 27, the imaging process is only appropriate to describe the anatomic 
situation and the dimensions of the tumor, and to provide a definitive diagnosis. 
The final diagnosis of primary sacral tumor can be made after an accurate histological examination. 
Open biopsy is considered to be the so-called gold standard for the diagnosis of bone lesions, with 
98% accuracy 28. Recently, percutaneous CT guided needle biopsy has gained popularity, showing a 
good accuracy with a less invasive procedure. A meta-analysis of spinal percutaneous biopsies 
estimated its accuracy to 92%29. In a systematic review Yamazaki et al. assessed the effect of 
incisional biopsy on the surgical outcome, and found that incisional biopsy significantly increases the 
risk of recurrence of primary spine tumors30. 
Limitation of the non-surgical therapy  
The primary goal of the therapeutic process is to be curative. Treatment options of primary 
malignant sacral tumors should be discussed by a multidisciplinary team, including oncologists, 
radiologists, radiotherapists and spine surgeons. This special group should decide on the strategy of 
the treatment, selecting the optimal combination of conventional chemo- or raditherapeutic 
modalities, as well as to indicate the role of the surgical intervention.  The decision depends on the 
location, extent and biological aggressiveness of the lesion, and it is influenced by the general 
condition of the patient and by the accessibility to the highly sophisticated medical interventions.    
Majority of primary sacral tumors, including chordoma and chondrosarcoma, are relatively resistant 
to the conventional radio- or chemotherapy, although radiotherapy can be used as an adjunctive 
treatment in case of intralesional surgical resection6. In the case series of York et al. adjuvant 
radiotherapy tripled the disease-free survival time in chordomas31. Biologically higher doses are 
achievable with charged particle beam radiation therapies (i.e., protons, helium, neon, and carbon 
ions). Due to increased effective doses and the lower incidence of side effects, carbon-ion 
radiotherapy32, 33, and high-dose proton/photon therapy34, was reported to have better results 
compared with conventional radiotherapy. In contrast to conventional radiotherapy, where the full 
dose is delivered to the sacrum, cauda equina and the surrounding soft tissues, intensity-modulated 
radiation therapy (IMRT), stereotactic radiosurgery and the CyberKnife can deliver a high-dose single 
fraction to the target tissue sparing most of the adjacent neural or visceral elements35-37. The effect 
of the different radiation therapies can be further enhanced by the utilization of radiosensitizing 
agents like razoxane38, 39. 
Chemotherapy has never played a significant role in the treatment of low-grade sacral malignancies. 
Reports of tumor responses to regimens, including anthracyclines, cisplatin and alkylating agents, are 
only anecdotal40.  Recently, medical oncologists have pointed out the apparent sensitivity of 
chordoma to new molecular-targeted agents like imatinib, cetuximab and gefitinib41. Unfortunately 
these novel drugs are only accessible in clinical studies, and only for patients with unresecteble or 
metastatic tumors42. Chemotherapy is not effective in chondrosarcoma, however new 
chemotherapeutic agents like pemetrexed or sumantinib are currently evaluated43, 44. 
A decade ago the treatment of choice in high-grade primary malignant sacral tumors, like Ewing 
sarcoma and osteosarcoma was surgical intervention3. Today, due to the development of novel 
chemotherapeutic agents the surgical intervention has become the last step. In a systematic review, 
Sciubba et al. concluded that in the case of spinal Ewing sarcoma and osteosarcoma neoadjuvant 
chemotherapy and multimodality management offers a significant improvement in local control and 
long-term survival3. Surgery plus modern multidrug chemotherapy has dramatically increased the 5-
year disease-free survival rate of osteosarcoma patients to 60–70%, and in the case of Ewing 
sarcoma patients to 80%45, 46. Although the treatment of choice of Ewing sarcoma and osteosarcoma 
is chemotherapy, even with effective chemotherapy, these tumors are rarely cured without surgical 
resection47, 48. 
Surgical classification and planning 
In the mobile spine two staging system are frequently utilized. The Enneking surgical staging system 
of bone tumors 49 is widely used for planning the surgery of limb lesions (introducing the concepts (1) 
intralesional: piecemeal debulking or curettage, (2) marginal: lesion shelled out leaving 
pseudocapsule or reactive zone, (3) wide: intracompartmental en bloc, and (4) radical: 
extracompartmental excision). The adoption of this classification in the management of primary 
spine tumors is difficult because it did not takes in account the epidural compartment, the neurologic 
implication of sacrificing the spinal cord and roots, and the need for restoring spinal stability50. The 
Weinstein-Boriani-Biagini (WBB) staging system51 is a newer classification for spinal tumors 
developed in 1996 by three international cancer institutions (Rizzoli Institute, Mayo Clinic, and the 
University of Iowa Hospitals and Clinics). The fundamental concept of this system is to spare the 
spinal cord without compromising the surgical margins. As, the surgeons need to take in 
consideration other critical structures (including the rectum, cauda equina and iliac vessels), the 
preservation or reconstruction of the lumbo-pelvic junctions stability, these commonly used staging 
systems are difficult to apply in sacral tumors 52. Currently, there are no validated and widely used 
surgical staging systems which take in account all these issues.  
Recently Zhang et al. based on own clinical experience proposed a novel classification system for 
sacral tumors52. The classification system is a combination of the WBB and Enneking tumor staging 
methods, and contains 16 possible categories. Sacral tumors are divided into 2 major types (above or 
below S-2) and then 4 further subtypes (based on the extension of the tumor in the pelvic cavity: < 5 
cm or ≥ 5 cm). A further subdivision (similar to the WBB system) is then added according to the axial 
plane anatomy (3 zones: anterior sacrum, posterior sacrum, and lateral sacrum). Fehlings listed a 
number of limitations of this novel system: the study is based on retrospective series, has small 
number of diverse tumor types, moreover the tumor size, involvement of other organs, and distant 
metastases, were not considered53. 
In the planning process of the surgical treatment, the classification described by Fourney at al. (based 
on the level of nerve root sacrifice) could be useful in the everyday clinical experience54. They 
categorized sacral resections into two groups, midline tumors and eccentric lesions (Table 2.). The 
midline group included low, middle, and high sacral amputations, total sacrectomy, and 
hemicorporectomy. In the case of low sacral amputation the resection was performed at the level of 
the S4 nerve roots, in the case of midsacral amputation the resection was at the S3 nerve roots, and 
in the case of high sacral amputation at the level of the S2 nerve roots. If the tumor reached the S1 
nerve roots, then total sacrectomy was the treatment of choice. Hemicorporectomy (translumbar 
amputation) was indicated for localized, aggressive tumors that had spread beyond the sacrum to 
the lumbar spine. If the tumor was located in unilateral position and the planned resection does not 
exceeded the midline, they introduced the term “eccentric resection” including tumors overgrowing 
the sacroiliac joint and penetrating to the pelvic bones or to the extraosseal compartments (Figure 
2).  
Surgical approach  
En bloc resection of primary malignant sacral tumors can be performed from anterior, posterior, 
lateral and combined surgical approaches55. The decision in the use of the different approaches is 
depending on the tumor localization and the relationship with the surrounding anatomical 
structures. 
Traditionally, en bloc total and high sacrectomies were performed by using a combined anterior and 
posterior approach54. The anterior approach allowed the surgeon to expose the ventral aspect of the 
tumor, to identify and dissect the internal iliac vessels and the rectum, and allowed to determine the 
proper plane of the resection. If needed a rectus flap can be prepared for closure of the large 
posterior surgical defect (VRAM). The posterior approach was then used for tumor removal and 
spino-pelvic reconstruction54, 55. In the case of low and mid sacral resection the en bloc tumor 
removal was feasible through a posterior approach only56, 57. Recently, Clarke et al. recommended 
the use of the posterior-only approach for all sacral tumors that do not extend beyond the 
lumbosacral junction or invade the pelvic organs58. Sherman et al. reported acceptable morbidity 
after posterior-only sacral tumor en bloc resection59. In their prospective observational study on 
positioning related morbidity only obesity and procedure times greater than ten hours were 
identified as risk factors. In case when the tumor extends through the sacroilliac joint to the iliac 
bone the eccentric sacrectomy should be combined with hemipelvectomy54. In this case in their 
opinion the proper surgical approach is the lateral decubitus position60. 
Another important aspect that should be kept in mind is the inclusion of the biopsy tract in the 
resection. In case of open and CT-guided biopsies, seeding of the biopsy tract or the surgical field 
may occur during the procedure. Therefore, the surgeon should be involved into the planning of the 
biopsy, assuring that the biopsy tract will be excised en bloc with the tumor specimen6. 
Tumor resection 
To achieve a long-term local oncological control, en bloc resection with wide surgical margins is the 
optimal technique in the surgical management of the malignant tumors of the sacrum2, 30. 
Incomplete tumor resection leads to a fast local regrowth, while intralesional resections imply higher 
local recurrence rate and decreased survival7, 61. However en bloc total or partial sacrectomy is an 
uncommon surgery and has a number of challenging factors, including age, the patient’s 
preoperative general condition, the extension of the tumor, and its relationship with surrounding 
anatomic structures54. Neurological structures infiltrated by the tumor often must be sacrificed to 
achieve proper local control. Depending on the neurological level of the resection this can lead to 
lower extremity sensory or motor deficits, as well as bowel or bladder incontinence and sexual 
dysfunction62. Rectal involvement by the sacrococcygeal tumor is not common; in these cases the 
proper en bloc resection should include the rectum, requiring colostomy before sacral resection63. 
Partial or total resection of the piriformis and gluteus muscles or sacroiliac joints is an important 
factor to achieve proper surgical margins and prevent local recurrence1, 64. The quality of surgical 
margins had been recently described as the main prognostic factor for local recurrence7, 54, 58, 65. 
Ruggieri et al. reported that achieving wide resection margins at the initial surgery is the most 
important predictor of local recurrence and survival7. 
Fuchs et al. performed sacral resection in 52 chordomas66. The surgical approach depended on the 
level and extent of the lesions, they used posterior approach in twenty-two patients and combined 
anterio-posterior approach in thirty patients. A wide surgical margin was achieved in 40% of the 
patients and 23 patients had local recurrence. The rate of recurrence-free survival was 59% at five 
years and 46% at ten years. The overall survival rates were 74%, 52%, and 47% at five years, ten 
years, and fifteen years, respectively. They found that the wide surgical margin was the most 
important predictor of survival and of local recurrence in patients with sacrococcygeal chordoma. 
They also concluded that the use of a combined anterio-posterior approach increased the likelihood 
of obtaining a wide margin. 
In contrast Clarke et al. assessed 36 consecutive sacral chordoma patients who underwent primary 
posterior-only en bloc sacral resections58. They defined sacral amputation level by the sacral root 
preservation, thus performing in two cases total, in eight cases high, in nine cases middle, in 12 cases 
low, and in five cases distal sacrectomy. The surgical margins were marginal in 34 cases and 
contaminated in two patients. In the two year follow up they found only 20% of recurrence or distant 
metastases. 
The same principle of posterior only sacral tumor resection is promoted by Angelini et al.67. They 
used a novel technique (modified Osaka Technique) to perform the resection of the sacrum in 13 
primary sacral tumor patients. The technique uses a device similar to the modified threadwire saw 
for sacral osteotomies developed by Tomita and Kawahara68, and subsequently modified by Osaka et 
al.69. This new technique allows wide margins with preservation of roots, and reduction in blood loss 
and operative time. They even indicate this modified posterior-only approach to resections proximal 
to S3, when there is only minimal invasion of the pelvic and sacroiliac joints. They achieved proximal 
resection in nine patients and distal in four patients, with wide margins in ten patients, marginal in 
one, and intralesional in two cases. With a mean follow-up of 35.5 months they reported 9 disease 
free patients and 4 recurrences. 
Stabilization 
If sacral tumor resection spares the sacroiliac joint, lumbo-pelvic stability is considered to be 
preserved54. In cases of high sacral resections where minimum of 50% of the sacroiliac joint is 
affected, reconstruction becomes mandatory70. Bergh et al. found that 33% of 18 patients with high 
sacral amputation suffered fatigue fractures of the sacral remnant61. In the experience of Fourney et 
al. lumbo-pelvic reconstruction was unnecessary after hemisacrectomy when the contralateral 
sacroiliac joint was intact, and there was no anterior pelvic deficiency54. Instrumentation provides 
good stability until fusion occurs, but biological osseous union is the only reliable method of long-
term fixation6. However there are no reports in the literature about the long term outcome of the 
lumbo-pelvic fusion rate after total sacrectomies.    
A wide range of lumbopelvic instrumentations had been used previously for reconstruction after 
total sacrectomy. In the 1980’s, Harrington rod technology and combinations of hooks and wires 
were chosen for lumbo-pelvic reconstruction71. This was followed by the use of the more advanced 
Cotrel–Dubousset rods and hooks with the sacral bars (or AOplates)72. In the 1990’s, the pedicle 
screw-Galveston L-rod construct combination was developed71. Beside these reconstruction methods 
several techniques have been published, including modified Galveston reconstruction73, triangular 
frame reconstruction74, sacral-rod reconstruction (SRR)75, four-rod reconstruction (FRR)76, bilateral 
fibular flaps reconstruction (BFFR)77and the closed-loop reconstruction57. 
Because of the risk of infection and hardware failure, some authors have recommended that 
reconstruction should be avoided even in the case of total sacrectomies. Wuisman et al. reported 
successful mobilization in five patients more than eight weeks after total sacrectomy without any 
form of reconstruction78. Ruggieri et al. advocates similar principles7, 79. In their experience, after 
total sacrectomy, the lumbar spine migrates inferiorly and remains between the ilia. The muscles and 
scar tissue between the pelvis and spine form a biologic sling eventually stabilizing the spine.  
After tumor resection, one of the greatest difficulties is the closure of the large sacrectomy defect. 
Several reconstructive techniques were used for soft tissue reconstruction to prevent rectal prolapse 
and wound healing complications. The vertical rectus abdominis myocutaneous flap and gluteus 
maximus adipomuscular flaps were used with the best functional results by several authors80-83. 
Outcome  
As sacral tumor surgery is characterized by complex surgical techniques, prolonged operating time 
and severe bleeding, the likelihood of perioperative complications is high. During the surgery, 
unplanned nerve root resections, visceral and vascular perforations may occur and intraoperative 
death is also a possible severe complication. In the early postoperative period the development of 
different wound or surgical site infections may require additional surgical interventions. Proximity to 
the perineal region, poor blood supply of the skin flap, the huge cavity and the neural atrophy can 
increase the chance of wound complications. Infection and wound healing complications are 
common after the resection of sacral tumors ranging from 25% to 50% in the literature (Table 3.)31, 54, 
58, 61, 64-67, 77, 79, 84-93. 
Ruggieri et al. found a significant correlation between the curative, high sacral resections and the 
development of wound complications79. Their deep wound infection rate after 52 sacrectomies was 
44%. In contrast, they had no complication in their series of 27 intralesional sacral GCT resections79. 
Although the majority of the resections were high resections, lumbo-pelvic stabilization was not 
needed. They did not stabilize even the two patients with total sacral resection because of the risk of 
major wound complications and considering the acceptable ambulatory status of the patients. 
Beadel et al. reported similar findings94. In 16 patients treated with iliosacral resection for primary 
tumors the incidence of infection was 43% (7/16 cases). Comparing the 4 patients who had lumbo-
pelvic reconstruction and the 12 patients without reconstruction, the infection rate was higher in the 
first group (75%) than in the latter group (33%). Recently, Li et al. have published a large series of 
sacral resections and analyzed the factors associated with wound complications95. Of the 387 
patients 274 healed uneventfully, and 113 (29.2 %) had wound infection or dehiscence. They found 
that previous irradiation, rectum rupture, younger age, history of diabetes mellitus, large tumor 
volume, and instrumentation used are risk factors for wound complications. 
The planed or incidental resection of the sacral nerve roots results in different degree of neurological 
deficit. As reported by Stener and Gunterberg impairment of ambulatory ability, sphincter function, 
and sexual capacity were related to the number of preserved nerve roots96, 97. The third sacral roots 
are vital for visceral function, the preservation of the bilateral S2 might result in minor and 
temporary sphincter dysfunction84. Fourney et al. reported that their patients with amputations 
distal to S3 generally experienced limited deficits, with preservation of sphincter function in the 
majority and some reduced perineal sensation54. Gunterberg et al. found that unilateral sacral root 
dissection does not have significant consequences96. Similarly Fourney et al. published that unilateral 
resection of sacral roots led to unilateral motor deficits; sphincter control can be either preserved or 
only partially compromised54. Protection of L5 and S1 nerve roots is important for ambulation. If both 
S1 roots are sacrificed, there is consistent loss of sphincter control and sexual ability, however, 
patients with intact L5 nerves, generally are able to walk without external support54.  
The oncological outcome is associated with the surgical margins. In case of intralesional resections, 
the local recurrence rate can be as high as 83%31. On the other hand, in en bloc wide resections the 
local recurrence can be also high ranging between 30 and 60% (Table 3.). York et al. reported in 1999 
15 sacral chordoma cases with wide resection from which eight (53%) relapsed during the follow up. 
In the series of Bergh et al. six of 16 patients with wide resection (37%) experienced local 
recurrence61. Bergh et al. concluded that the initial surgery performed elsewhere, larger tumor size 
and inadequate surgical margins were adverse prognostic factors for local recurrence. In the case-
series of Fuchs et al., 52 patients had been followed for an average of 7.8 years after operative 
treatment of sacral chordoma66. They had an overall local recurrence rate of 44% but only one of the 
21 wide resection cases relapsed (5%). The authors reported inadequate margins in 60% of the 
patients. The mortality rate was 26%, 48%, and 53% at five, ten, and fifteen years, respectively. 
Fourney et al., in their series, treated 21 patients with malignant primary sacral tumors54. In 13 
patients the resection was wide and it was marginal in eight cases. Local recurrence or metastasis 
occurred in 30% of the former and 50% of the latter cases, justifying that despite of the morbidity of 
a wide resection and the inadequate functional outcome, en bloc resection is essential to achieve 
long-term disease control.  
Conclusion 
Most of the primary tumors of the sacrum are low-grade malignant neoplasm with nonspecific 
symptoms thus they can reach enormous dimensions before being diagnosed. The complexity of the 
sacral region further complicates the surgical treatment of these tumors. En bloc resection with wide 
surgical margins is essential for long-term local oncologic control, even though most of the patients 
might have significant complications. Considering the rarity of the disease and the complexity of the 
management, multicenter, prospective studies are required to provide high level of evidence and to 
develop not only the optimal standard surgical procedures but also the new, adjuvant therapeutic 
options which are still missing. 
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Figures 
Table 1. Diagnostic characteristics of Malignant Primary Sacral Tumors 
Tumor CT MR 
Chordoma 
 Expansive 
 Lytic 
 Sclerotic 
 Intratumoral calcifications 
 T1 hypointense 
 T2 hyperintense 
 Gd* enhancment 
Chondrosarcoma 
 Expansive 
 Lytic 
 Bone destruction 
 Soft tissue expansion 
 T1 hypontense to isointense 
 T2 hyperintense 
 Gd ‘‘rings and arcs’’ pattern 
Ewing sarcoma 
 Lytic 
 Sclerotic 
 T1 isointense 
 T2 isointense to hyperintense 
 Gd enhancment 
Osteosarcoma 
 Lytic 
 Destructive 
 Matrix mineralization 
 T1 hypointense 
 T2 hyperintense 
*Gd: Gadolinium 
  
Table 2. Classification of en bloc sacral tumor resections after Fourney54  
Type of  Sacrectomy Nerve Root(s) 
Sacrificed 
Approach Lumbopelvic 
reconstruction 
Midline    
Low S-4 & below Posterior No 
Middle S-3 & below Posterior No 
High S-2 & below Anterior-posterior No 
Total bilateral S1–5 Anterior-posterior Yes 
Hemicorporectomy translumbar Supine-lateral No 
Lateral    
Hemisacrectomy unilateral (variable) Lateral No 
 
  
Table 3.  
  
  
Figure 1.  
Categorization of sacral resections after Fourney54; A. Low sacral amputation - the sacrifice of S4 
nerve roots B. Midsacral amputation - the sacrifice of the S3 nerve roots C. High sacral amputation - 
the sacrifice of the S2 nerve roots D. Total sacrectomy - the sacrifice of the S1 nerve roots E. 
Hemicorporectomy (translumbar amputation) - for aggressive tumors that had spread beyond the 
sacrum to the lumbar spine F. Eccentric resection - for tumors that does not exceed the midline 
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